Skip to main content

Peer Review reports

From: Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database

Original Submission
30 Mar 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
10 Sep 2021 Reviewed Reviewer Report
18 Sep 2021 Reviewed Reviewer Report - Kouseki Hirade
29 Sep 2021 Author responded Author comments - Tuhin Maity
Resubmission - Version 3
29 Sep 2021 Submitted Manuscript version 3
29 Sep 2021 Author responded Author comments - Tuhin Maity
Resubmission - Version 4
29 Sep 2021 Submitted Manuscript version 4
6 Oct 2021 Author responded Author comments - Tuhin Maity
Resubmission - Version 5
6 Oct 2021 Submitted Manuscript version 5
9 Oct 2021 Author responded Author comments - Tuhin Maity
Resubmission - Version 6
9 Oct 2021 Submitted Manuscript version 6
14 Oct 2021 Reviewed Reviewer Report
16 Oct 2021 Reviewed Reviewer Report - Kouseki Hirade
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
27 Oct 2021 Editorially accepted
13 Nov 2021 Article published 10.1186/s12913-021-07260-z

You can find further information about peer review here.

Back to article page